Dapagliflozin in Patients with Chronic Kidney Disease

J.L. Heerspink, Hiddo; V. Stefánsson, Bergur; Correa‐Rotter, Ricardo; M. Chertow, Glenn; Greene, Tom; Fan Hou, Fan; F.E. Mann, Johannes; J.V. McMurray, John; Lindberg, Magnus; Rossing, Peter; David Sjöström, C.; D. Toto, Roberto; Langkilde, Anna-Maria; C. Wheeler, David

doi:10.1056/nejmoa2024816

Public

Dapagliflozin in Patients with Chronic Kidney Disease

Published in New England Journal of Medicine • Sep 24, 2020

Authors:

Hiddo J.L. Heerspink

Bergur V. Stefánsson

Ricardo Correa‐Rotter

Abstract

BACKGROUND: Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known. METHODS: of body-surface area and a urinary albumin-to-creatinine ratio...

Subject

Dapagliflozin

Kidney disease

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!